High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease

Journal of the American College of Cardiology

Volumn 68, Issue 25, 2016, Pages 2719-2728

  Ford, Ian ^a   Shah, Anoop S V ^b   Zhang, Ruiqi ^a   McAllister, David A ^c   Strachan, Fiona E ^b   Caslake, Muriel ^a   Newby, David E ^b   Packard, Chris J ^a   Mills, Nicholas L ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

cardiac troponin; cardiovascular risk; primary prevention; statins

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; PLACEBO; PRAVASTATIN; TROPONIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TROPONIN I;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; CORONARY DISEASE; DRUG EFFECTS; ELECTROCARDIOGRAPHY; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PRIMARY PREVENTION; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SCOTLAND; SURVIVAL RATE; TRENDS;

CORONARY DISEASE; ELECTROCARDIOGRAPHY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SCOTLAND; SURVIVAL RATE; TROPONIN I;

EID: 85006375573     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.10.020     Document Type: Article

References (27)

1. 1 Shepherd, J., Cobbe, S.M., Ford, I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995), 1301–1307.
2. 2 Ford, I., Murray, H., Packard, C.J., Shepherd, J., Macfarlane, P.W., Cobbe, S.M., Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 357 (2007), 1477–1486.
3. 3 Downs, J.R., Clearfield, M., Weis, S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998), 1615–1622.
4. 4 Ridker, P.M., Danielson, E., Fonseca, F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
5. 5 Redberg, R.F., Katz, M.H., Healthy men should not take statins. JAMA 307 (2012), 1491–1492.
6. 6 Abramson, J.D., Rosenberg, H.D., Jewell, N., Wright, J.M., Should people at low risk of cardiovascular disease take a statin?. BMJ, 347, 2013, f6123.
7. 7 Pencina, M.J., Navar-Boggan, A.M., D'Agostino, R.B. Sr., et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 370 (2014), 1422–1431.
8. 8 Omland, T., de Lemos, J.A., Sabatine, M.S., et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 361 (2009), 2538–2547.
9. 9 de Lemos, J.A., Drazner, M.H., Omland, T., et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 304 (2010), 2503–2512.
10. 10 deFilippi, C.R., de Lemos, J.A., Christenson, R.H., et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 304 (2010), 2494–2502.
11. 11 Eggers, K.M., Venge, P., Lindahl, B., Lind, L., Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J Am Coll Cardiol 61 (2013), 1906–1913.
12. 12 Zeller, T., Tunstall-Pedoe, H., Saarela, O., et al. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J 35 (2014), 271–281.
13. 13 Omland, T., Pfeffer, M.A., Solomon, S.D., et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol 61 (2013), 1240–1249.
14. 14 Kavsak, P.A., Xu, L., Yusuf, S., McQueen, M.J., High-sensitivity cardiac troponin I measurement for risk stratification in a stable high-risk population. Clin Chem 57 (2011), 1146–1153.
15. 15 The West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men aged 45-64 years: trial design. J Clin Epidemiol 45 (1992), 849–860.
16. 16 Shah, A.S., Griffiths, M., Lee, K.K., et al. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ, 350, 2015, g7873.
17. 17 Packard, C.J., O'Reilly, D.S., Caslake, M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343 (2000), 1148–1155.
18. 18 Lowe, G., Rumley, A., Norrie, J., et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study. Thromb Haemost 84 (2000), 553–558.
19. 19 Sattar, N., Gaw, A., Scherbakova, O., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003), 414–419.
20. 20 Everett, B.M., Zeller, T., Glynn, R.J., Ridker, P.M., Blankenberg, S., High-sensitivity cardiac troponin I and B-type natriuretic peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation 131 (2015), 1851–1860.
21. 21 Shah, A.S., Anand, A., Sandoval, Y., et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet 386 (2015), 2481–2488.
22. 22 Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:25 Pt B (2014), 2889–2934.
23. 23 White, H.D., Tonkin, A., Simes, J., et al. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease). J Am Coll Cardiol 63 (2014), 345–354.
24. 24 Tousoulis, D., Psarros, C., Demosthenous, M., et al. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol 63 (2014), 2491–2502.
25. 25 Chin, C.W., Shah, A.S., McAllister, D.A., et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur Heart J 35 (2014), 2312–2321.
26. 26 Wu, A.H.D., Biological and analytical variation of clinical biomarker testing: implications for biomarker-guided therapy. Curr Heart Fail Rep 10 (2013), 434–440.
27. 27 Todd, J., Freese, B., Lu, A., et al. Ultrasensitive flow-based immunoassays using single-molecule counting. Clin Chem 53 (2007), 1990–1995.